Malaria and iron: History and review Malaria and iron Eugene D. Weinberg and Jym Moon

Drug Metabolism Reviews

Volumn 41, Issue 4, 2009, Pages 644-662

  Weinberg, Eugene D ^a   Moon, Jym ^b  

^a INDIANA UNIVERSITY   (United States)

^b Scott Community College   (United States)

Author keywords

Artemisinin; Chloroquine; Heme; Hemozoin; Iron(III) chelators; Malaria; Plasmodium falciparum

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; ADENOSINE TRIPHOSPHATASE (CALCIUM); ANTIMALARIAL AGENT; ARTEETHER; ARTEMETHER; ARTEMISININ; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DIHYDROARTEMISININ; FANSIDAR; FERROUS SULFATE; FOLIC ACID; FOLIC ACID ANTAGONIST; HYDROXAMIC ACID DERIVATIVE; IRON; IRON CHELATING AGENT; MEFLOQUINE; MEPACRINE; PLACEBO; PRIMAQUINE; PYRIMETHAMINE; QUININE; RIBONUCLEOTIDE REDUCTASE; SULFADOXINE; SULFANILAMIDE DERIVATIVE; TRIOXAQUINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ANTIMALARIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; ENERGY YIELD; HUMAN; INFECTION RISK; IRON OVERLOAD; MALARIA; MALARIA FALCIPARUM; NONHUMAN; REVIEW; RISK FACTOR;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE, MICROBIAL; HISTORY, 20TH CENTURY; HUMANS; IRON; IRON CHELATING AGENTS; MALARIA, FALCIPARUM; MOLECULAR STRUCTURE; PLASMODIUM FALCIPARUM;

EID: 70350044887     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/03602530903178905     Document Type: Review

References (248)

1. Adam, Z. (1996). Iron supplementation and malaria: a randomized, placebo-controlled feld trial in rural Ethiopia [doctoral thesis]. London: University of London.
2. Adams, P.A., Egan, T. J., Ross, D. C, Silver, J., Marsh, P. J. (1996). Te chemical mechanism of fj-hematin formation studied by Mössbauer spectroscopy. Biochem J 318:25-27.
3. Akinyanju, O., Goddell, J. C, Ahmed, I. (1973). Pyrimethamine poisoning. Br Med J 4:147-148.
4. Anderegg, G., L'Eplattenier, F., Schwarzenbach, G. (1963). Hydroxamate complex II. Te employment of the pH method. Helv Chim Acta 46:1400.
5. Anderegg, G, Raber, M. (1990). Metal complex formation of a new siderophore desferrithiocin and of three related ligands. J Chem Soc Chem Commun 17:1194-1196.
6. Asawamahasakda, W., Ittarat, I., Chang, C. C, McElroy, P., Meshnick, S. R. (1994). Efects of antimalarials and protease inhibitors on plasmo-dial hemozoin production. Mol Biochem Parasitol 67:183-191.
7. Aviado, D. M., Marco, V., Weed, D. (1968). Pharmacology of new antimalarial drugs: RC12, sodium antimony salt of astiban, and kethoxal-bis-thiosemicarbazone. Chemotherapy 13:339-355.
8. Baker, E., Wong, A., Peter, H., Jacobs, A. (1992). Desferrithiocin is an efective iron chelator in vivo and in vitro but ferrithiocin is toxic. Br J Haematol 81:424-431.
9. Banerjee, R., Liu, J., Beatty, W., Pelosof, L., Klemba, M., Goldberg, D. E. (2002). Four plasmapepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci U S A 99:990-995.
10. Barrett, J. F. R., Whittaker, P. G., Williams, J. G., Lind, T. (1994). Absorption of non-haeme iron from food during normal pregnancy. Br Med J 309:79-82.
11. Basilico, N., Pagani, E., Monti, D., Olliaro, P., Taramelli, D. (1998). A microtitre-based method for measuring the haeme polymerization inhibitory activity (HPIA) of antimalarial drugs. Antimicrob Chemother 42:55-60.
12. Becuwe, P., Gratepanche, S., Fourmaux, M. N., Van Beeumen, J., Samyn, B., Mercereau-Puijalon, O., et al. (1996). Characterization of iron-dependent endogenous superoxide dismutase of Plasmodium falciparum. Mol Biochem Parasitol 76:125-134.
13. Benoit-Vical, F., Lelièvre, J., Berry, A., Deymier, C, Dechy-Cabaret, O., Cazelles, J., et al. (2007). Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. Antimicrob Agents Chemother 51:1463-1472.
14. Berberian, D. A., Slighter, R. G. Jr., (1973). Chemotherapeutic activity of combination doses of chloroquine, pyrimethamine, sulfam-ethoxydiazine, a long-acting sulfanilamide, against Plasmodium berghei infections in mice. Antimicrob Agents Chemother 3:392-398.
15. Berger, J., Dyek, J. L., Galou, P., Aplogan, A., Schneider, D., Traissac, P., et al. (2000). Efect of daily iron supplementation on iron status, cell-mediated immunity, and incidence of infections in 6-36-month Tongolese children. Eur J Clin Nutr 54:29-35.
16. Bergeron, R. J., Streif, R. R., Creary, E. A., Daniels, R. D., Jr., King, W., Luchetta, G., et al. (1993). A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxam-ine B in Cebus monkey model. Blood 81:2166-2173.
17. Bergeron, R. J., Streif, R. R., Wiegand, J., Vinson, T., Luchetta, G., Evans, K. M., et al. (1990). A comparative evaluation of iron clearance models. Ann N Y Acad Sci 612:378-393.
18. Bergeron, R. J., Wiegand, J., Brittenham, G. M. (1998). HBED: A potential alternative to deferoxamine for iron-chelating therapy. Blood 91:1446-1452.
19. Bergeron, R. J., Wiegand, J., Brittenham, G. M. (1999). HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy. Blood 93:370-375.
20. Bergeron, R. J., Wiegand, J., Brittenham, G. M. (2002a). HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood 99:3019-3926.
21. Bergeron, R. J., Wiegand, J., Dionis, J. B., Egli-Karmakka, M., Frei, J., Huxley-Tencer, A., et al. (1991). Evaluation of desferrithiocin and its synthetic analogues as orally efective iron chelators. J Med Chem 34:2072-2078.
22. Bergeron, R. J., Wiegand, J., McManis, J. S., Bharti, N., Singh, S. (2008). Desferrithiocin analogues and nephrotoxicity. J Med Chem 51:5993-6004.
23. Bergeron, R. J., Wiegand, J., McManis, J. S., Vinson, J. R. T., Yao, H., Bharti, N., et al. (2006). (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4- methyl-4-thiazolecarboxylic acid polyesters: a solution to nephrotoxicity. J Med Chem 49:2772-2783.
24. Bergeron, R. J., Wiegand, J., McManis, J. S., Welmar, W. R., Huang, G. (2002b). Structure-activity relationships among desazadesfer-rithiocin analogues. Adv Exp Med Biol 509:167-184.
25. Bergeron, RJ, Wollenweber, M, Wiegand, J. (1994). An investigation of desferrithiocin metabolism. J Med Chem 37:2889-2895.
26. Berliner, R. W., Earle, D. P., Jr., Taggart, J. V., Zubrod, G., Welch, W. J., Conan, N. J., et al. (1948). Studies on the chemotherapy of the human malarias. VI. Te physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline. J Clin Invest 27:(Suppl):98.
27. Biot, C., Pradines, B., Sergeant, M. H., Gut, J., Rosenthal, P. J., Chibale, K. (2007). Design, synthesis, and antimalarial activity of structural chimeras of thiosemicarbazone and ferroquine analogues. Bioorg Med Chem Lett 17:6434-6438.
28. Boone, K. E., Watters, D. A. K. (1995). Te incidence of malaria after splenectomy in Papua New Guinea. Br Med J 311:1273.
29. Brittenham, G. M. (1990). Pyridoxal isonicotinoyl hydrazone: an efective iron-chelator after oral administration. Semin Hematol 27:112-116.
30. Brossi, A., Venugopaplau, B., Gerpe, L. D., Yeh, H. J.C., Flippen-Anderson, J. L., Luo, X. D., et al. (1988). Arteether, a new antima-larial drug: synthesis and antimalarial properties. J Med Chem 31:645-650.
31. Bruce-Chwatt, L. J. (1982a). Qinghaosu: a new antimalarial. Br Med J 284:767-768.
32. Bruce-Chwatt, L. J. (1982b). Chemoprophylaxis of malaria in Africa: the spent "magic bullet." Br Med J 285:674-676.
33. Bruce-Chwatt, L. J. (1983). Malaria and pregnancy. Br Med J 286:1457-1458.
34. Buss, J. L., Greene, B. T., Turner, J., Torti, F. M., Torti, S. V. (2004a). Iron chelators in cancer chemotherapy. Curr Top Med Chem 4:1623-1635.
35. Buss, J. L., Neuzil, J., Ponka, P. (2004b). Oxidative stress mediates toxicity of pyridoxal isonicotinoyl hydrazone analogs. Arch Biochem Biophys 421:1-9.
36. Byles, A. B., D'Sa, A. (1970). Reduction of reaction due to iron dextran infusion using chloroquine. Br Med J 3:625.
37. Cabantchik, A. I., Glickstein, H., Golenser, J., Loyevsky, M., Tsafack, A. (1996). Iron chelators: mode of action as antimalarials. Acta Haematol 95:70-77.
38. Carter, R., Mendis, K. N. (2002). Evolutionary and historical aspects of the burden of malaria. Clin Microbiol Rev 15:564-594.
39. Chaston, T. B., Watts, R. N., Yuan, J., Richardson, D. R. (2004). Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves Fenton-derived free radical generation. Clin Cancer Res 10:7365-7374.
40. China Cooperative Research Group on Qinghaosu and Its Derivatives as Antimalarials. (1982). Chemical studies on qinghaosu (artem-isinin). J Trad Chin Med 2:3-8.
41. Ciba-Laboratories. (1964). Desferal®. A specifc iron-chelating agent. Horsham, Sussex, UK: Ciba Laboratories, Ltd.
42. Cikrt, M., Ponka, P., Necas, E., Neuwirt, J. (1980). Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br J Haematol 45:275-283. (Pubitemid 10120178)
43. Clark, I. A., Cowden, W. B/, Butcher, G. A. (1983). Free oxygen radical generators as antimalarial drugs. Lancet 1(8316):234.
44. Clark, I. A., Hunt, N. H., Cowden, W. B., Maxwell, L. E., Mackie, E. J. (1984). Radical-mediated damage to parasites and erythrocytes in Plasmodium vinckei-infected mice after injection of t-butyl hydroperoxide. Clin Exp Immunol 56:524-1230
45. Coslédan, F., Fraisse, L., Pellet, A., Guillou, F., Mordmüller, B., Kremsner, P. G., et al. (2008). Selection of a trioxaquine as an antimalarial drug candidate. Proc Natl Acad Sci U S A 105:17579-17584.
46. de Mast, Q., Nadim, B., Reyburn, H., Kemma, E. H., Amos, B., Laarakkers, C. H., et al. (2009). Assessment of urinary concentrations of hepcidin provides novel insight into disturbances in iron homeostasis during malarial infection. J Infect Dis 199:253-262.
47. de Oliveira, R. B., de Souza-Fagundes, E. M., Soares, R. P., Andrade, A. A., Dretti, A. U., Zani, C. L. (2008). Synthesis and antimalarial activity of semicarbazone and thiosemicarbazone derivatives. Eur J Med Chem 43:1983-1988.
48. Diro, M., Beydoun, S. N. (1982). Malaria in pregnancy. South Med J 75:959-963.
49. Dunaief, J. L. (2008). Patent title: use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease. IPC8 Class: AA61F200F1; USPC Class: 424427.
50. Dutta, G. P., Bajpai, R., Viswakarma, R. A., (1989). Artemisinin (qinghaosu)-a new gametocytocidal drug for malaria. Chemotherapy 35:200-207.
51. Eckman, J. R., Modler, S., Eaton, J. W., Berger, E., Engel, R. R. (1977). Host heme catabolism in drug-sensitive and drug-resistant malarial parasites. J Lab Clin Med 70:967.
52. Eckstein-Ludwig, U., Webb, R., Van Goethem, I. D., East, J. M., Lee, A. G., Kimura, M., et al. (2003). Artemisinins target the SERCA of Plasmodium falciparum. Nature 424:957-961.
53. Egan, T. J. (2008). Recent advances in understanding the mechanism of hemozoin (malaria pigment) formation. J Inorg Biochem 102:1288-1299.
54. Egan, T. J., Combrinck, J. M., Egan, J., Hearne, G. R., Marques, H. M., Ntenteni, S., et al. (2002). Fate of haem iron in the malaria parasite Plasmodium falciparum. Biochem J 365:343-347.
55. Egan, T. J., Ross, D. C., Adams, P. A. (1994). Quinoline anti-malarial drugs inhibit spontaneous formation of beta-hematin (malaria pigment). FEBS Lett 352:54-57.
56. Emery, T. F. (1991). Iron and your health: facts and fallacies. Boca Raton, Florida, USA: CRC Press, Inc.
57. Emery, T., Neilands, J. B. (1959). Te iron-binding center of ferri-chrome compounds. Nature 184:1632.
58. Emery, T., Neilands, J. B. (1961). Structure of the ferrichrome compounds. J Am Chem Soc 83:1626.
59. Erlandson, M. E., Walden, B., Stern, G., Hilgartner, M. W., Smith, C. H. (1962). Studies on congenital hemolytic syndromes. I V. Gastrointestinal absorption of iron. Blood 19:359-369.
60. Faller, B., Spanka, C., Sergejew, T., Tschinke, V. (2000). Improving the oral bioavailability of the iron chelator, HBED, by breaking the symmetry of the intramolecular H-bond network. J Med Chem 43:1467-1475.
61. FDA. (2005). FDA approves frst oral drug for chronic iron overload. FDA Press Release, November 2005. Silver Spring, Maryland, USA: U.S. Food and Drug Administration.
62. Fitch, C. D., Chevli, R., Banyal, H. S., Phillips, G., Pfaller, M. A., Krongstad, D. J. (1982). Lysis of Plasmodium falciparum by fer-riprotoporphyrin IX and a chloroquine-ferriprotoporphyrin IX complex. Antimicrob Agents Chemother 21:819-822,
63. Fritsch, G., Jung, A. (1986). 14C-desferrioxamine B: uptake into eryth-rocytes infected with Plasmodium falciparum. Z Parasitenkd 72:709-713.
64. Fritsch, G., Sawatzki, G., Treumer, J., Jung, A., Spira, D. T. (1987). Plasmodium falciparum: inhibition in vitro with lactoferrin, des-ferriferrithiocin, and desferricrocin. Exp Parasitol 63:1-9.
65. Fritsch, G., Treumer, J., Spira, D. T., Jung, A. (1985). Plasmodium vinckei:suppression of mouse infections with desferrioxamine B. Exp Parasitol 60:171-174.
66. Gabresselassie, H. (1996). Iron supplementation and malarial infection: results of a randomized, controlled feld trial [doctoral thesis]. Montreal, Quebec, Canada: McGill University.
67. Garah, F. B-E., Claparols, C., Benoit-Vical, F., Meunier, B., Robert, A. (2008). Te antimalarial trioxaquine, DU1301, alkylates heme in malaria-infected mice. Antimicrob Agents Chemother 52:2966-2969.
68. Glickstein, H., Breuer, W., Loyevsky, M., Konijn, A. M., Shanzer, A., Cabantchik, Z. I. (1996). Diferential cytotoxicity of iron chela-tors on malaria-infected cells versus mammalian cells. Blood 87:4871-4878.
69. Goldberg, D. E., Slater, A. F. G., Cerami, A., Henderson, G. B. (1990). Hemoglobin degredation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. Proc Natl Acad Sci U S A 87:2931-2935.
70. Golenser, J., Tsafack, A., Amichai, Y., Libman, J., Shanzer, A., Cabantchik, Z. I. (1995). Antimalarial action of hydroxamate-based iron chelators and potentiation of desferrioxamine action by reversed siderophores. Antimicrob Agents Chemother 39:61-65.
71. Golenser, J., Waknine, J. H., Krugliak, M., Hunt, N. H., Grau, G. E. (2006). Current perspectives on the mechanism of action of artemisinins. Int J Parasitol 36:1427-1441.
72. Gordeuk, V. R., Tuma, P. E., Brittenham, G. H., Zulu, S., Simwanza, G., Mhangu, A., et al. (1992b). Iron chelation with desferrioxamine B in adults with asymptomatic Plasmodium falciparum para-sitemia. Blood 79:308-312.
73. Gordeuk, V., Tuma, P., Brittenham, G., McLaren, C., Parry, D., Backenstose, A., et al. (1992a). Efect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. NEJM 327:1473-1477.
74. Goudeau, C., Loyevsky, M., Kassim, O. O., Gordeuk, V. R., Nick, H. (2001). Assessment of antimalarial efect of ICL670A on in vitro cultures of Plasmodium falciparum. Br J Haematol 115:918-923.
75. Grady, R. W., Hershko, C. (1990). HBED: a potential oral iron chela-tor. Ann N Y Acad Sci 612:361-368.
76. Grady, R. W., Salbe, A. D., Hilgartner, M. W., Giardina, P. J. (1994). Results from phase 1 clinical trial of HBED. Adv Exp Med Biol 356:351-359.
77. Haldar, K., Henderson, C. L., Cross, G. A. M. (1986). Identifcation of the parasite transferrin receptor of Plasmodium falciparum-in-fected erythrocytes and its acylation via 1,2-diacyl-SN-glycerol. Proc Natl Acad Sci.U S A 83:8565-8569.
78. Hall, A. P., Doberstyn, E. B., Karnchanachetanee, C., Samransamruajkit, S., Laixuthai, B., Pearlman, E. J., et al. (1977). Sequential treatment with quinine and mefoquine or quinine and pyrimethamine-sulf-adoxine for falciparum malaria. Br Med J 1:1626-1628.
79. Hall, A. P., Doberstyn, E. B., Mettaprakong, V., Sonkom, P. (1975). Falciparum malaria cured by quinine followed by sulfadoxine-pyrimethamine. Br Med J 2:15-17.
80. Hammadi, A., Ramiandrasoa, F., Sinou, V., Rogier, C., Fusai, T., Le Bras, J., et al. (2003). Cellular uptake of a catechol iron chelator and chloroquine into Plasmodium falciparum-infected erythro-cytes. Biochem Pharmacol 65:1351-1360.
81. Harvey, P., Heywood, P., Nesheim, M. C., Galne, K., Zedgans, M., Habicht, J. P., et al. (1989). Te efect of iron toxicity on malarial infection in Papua New Guinea school children. Am J Trop Hyg 40:12-18.
82. Haynes, R. K. (2008). From artemisinin to new artemisinin antima-larials: biosynthesis, extraction, old and new derivatives, stereochemistry, and medicinal chemistry requirements. Curr Top Med Chem 6:509-537.
83. Haynes, R. K., Chan, W. C., Lung, C. M., Uhlemann, A. C., Eckstein, U., Taramelli, D., et al. (2007). Te Fe2+-mediated decomposition, PfATP6 binding, and antimalarial activities of artemisone and other artemisinins: the unlikelihood of C-centered radicals as bioactive intermediates. Chem Med Chem 2:1480-1497.
84. Haynes, R. K., Krishna, S. (2004). Artemisinins: activities and actions. Microbes Infect 6:1339-1346.
85. Haynes, R. K., Monti, D., Taramelli, D., Basilico, N., Parapini, S., Oiliaro, P. (2003). Artemisinin antimalarials do not inhibit hemozoin formation. Antimicrob Agents Chemother 47:1175.
86. Haynes, R. K., Vonwiller, S. C. (1994). Extraction of artemisinin and artemisinic acid: preparation of artemether and new analogs. Trans R Soc Trop Med Hyg 88(Suppl 1):S23-S26.
87. Heppner, D. G., Hallaway, P. E., Kontoghiorghes, G. J., Eaton, J. W. (1988). Antimalarial properties of orally active iron chelators. Blood 72:358-361.
88. Hershko, C., Avramovici-Grisaru, S., Link, G., Gelfand, L., Sarel, S. (1981). Mechanism of in vivo iron chelation by pyridoxal isoni-cotinoyl hydrazone and other imino derivatives of pyridoxal. Lab Clin Med 98:99-108.
89. Hershko, C., Grady, R. W., Link, G. (1984a). Development and evaluation of the improved iron-chelating agents, EHPG, HBED, and their dimethyl esters. Haematologica (Budap) 17:25-33.
90. Hershko, C., Grady, R. W., Link, G. (1984b). Phenolic ethylenedi-amine derivatives: a study of orally efective iron chelators. Lab Clin Med 103:337-346.
91. Hershko, C., Peto, T. E. A., Weatherall, D. J. (1988). Iron and infection. Br Med J 296:660-664.
92. Hershko, C, Peto, T. E. A. (1988). Deferoxamine inhibition of malaria is independent of host iron status. J Exp Med 168:375.
93. Herzog, C., Kibbler, C. C., Ellis, C. J. (1983). Falciparum malaria resistant to chloroquine and fansidar: implications for prophylaxis. Br Med J 287:947-948.
94. Hess, U., Timmermans, P. H., Jones, M. (1983). Combined chloro-quine/Fansidar-resistant falciparum malaria appears in East Africa. Am J Trop Med Hyg 32:217-220.
95. Hider, R. C., Kontoghiorghes, G., Silver, J. (1982). UK Patent: GB-2118176.
96. Hider, R. C., Liu, Z. (1997). Te treatment of malaria with iron chela-tors. J Pharm Pharmacol 49:59-64.
97. Hofbrand, A. V., Cohen, A., Hershko, C. (2003). Role of deferiprone in chelation therapy for transfusional iron overload. Blood 102:17-24.
98. Huang, Y. L., Yang, Y. Z., Meshnick, S. R. (1994). Interaction of artemisi-nin with malarial hemozoin. Mol Biochem Parasitol 63:121-128.
99. Jambou, R., Legrand, E., Niang, M., Khim, N., Lim, P., Volney, B., et al. (2005) Resistance of Plasmodium falciparum feld isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366:1960-1963.
100. Jani, D., Nagarkatti, R., Beatty, W., Angel, R., Slebonick, C., Anderson, J., et al. (2008). HDP-a novel heme detoxifcation protein from the malaria parasite. PLoS Pathog 4:e1000053.
101. Kabyemela, E. R., Fried, M., Kurtis, J. D., Mutabingwa, T. K., Dufy, P. E. (2008). Decreasd susceptibility to Plasmodium falciparum in pregnant women with iron defciency. J Infect Dis 198:163-166.
102. Kalinowski, D. S., Richardson, D. R. (2005). Te evolution of iron chelators for the treatment of iron overload disease and cancer. Pharm Rev 57:547-582.
103. Kamchonwongpaisan, S., Paitayatat, S., Tebtaranonth, Y., Wilairat, P., Yuthavong, Y. (1995). Mechanism-based development of new antimalarials: synthesis of derivatives of artemisi-nin attached to iron chelators. Med Chem 38:2311-2316.
104. Kannan, R., Dinkar, S., Chauhan, V. S. (2002). Heme-artemisinin adducts are crucial members of the ability of artemisinin to inhibit heme polymerization. Chem Biol 9:321-332.
105. Kannan, R., Kumar, K., Sahal, D., Kukreti, S., Chauhan, V. S. (2005). Reaction of artemisinin with haemoglobin: implications for antimalarial activity. Biochem J 385:409-418.
106. Kapetanaki, S., Varotsis, C. (2000). Ferryl-oxo heme intermediate in the antimalarial mode of cation of artemisinin. FEBS Lett 474:238-241.
107. Kicic, A., Chua, A. C., Baker, E. (2001). Te desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents. Anticancer Drug Des 16:195-207.
108. Kimura, M., Yamaguchi, Y., Takada, S., Tanabe, K. (1993). Cloning of a Ca2+-ATPase gene of Plasmodium falciparum and comparison with vertebrate Ca2+-ATPases. J Cell Sci 104:1129-1136.
109. Klayman, D. L. (1985). Qinghaosu (artemisinin): an antimalarial drug from China. Science 228:1049-1055.
110. Klayman, D. L., Acton, N., Scovill, J. P. (1986). 2-acetylpyridine thiosemicarbazones. 12. Derivatives of 3-acetylisoquino-line as potential antimalarial agents. Arzneimittelforschung 36:10-13.
111. Klayman, D. L., Bartosevich, J. F., Grifn, T. S., Mason, C. J., Scovill, J. P. (1979). 2-acetylpyridine thiosemicarbazones. 1. A new class of potential antimalarial agents. J Med Chem 22:855-862.
112. Klayman, D. L., Mason, C. J., Scovill, J. P. (1984a). 2-acetylpyridine thiosemicarbazones. 10. 2-propionyl-, 2-butyryl-, and 2-(2-methylpropionyl) pyridine thiosemicarbazones as potential antimicrobial agents. Arzneimittelforschung 34:1701-1703.
113. Klayman DL, Scovill JP, Bruce J, Bartosevich J F. (1984b). 2-Acetylpyri-dine thiosemicarbazones: 8. Derivatives of 1-acetylisoquinoline as potential antimalarial agents. J Med Chem 27:84-87.
114. Klayman DL, Scovill JP, Bartosevich JF, Bruce J. (1983). 2-Acetylpyrid-ine thiosemicarbazones. 5. 1-[1-(2-Pyridyl)ethyl]-3-thiosemicar- bazides as potential antimalarial agents. J Med Chem 26:35-39.
115. Kontoghiorghes GJ. (1982). [Ph.D. thesis]. University of Essex, Colchester, UK: British Library (microflm catalog no.: D66194/86).
116. Krishna, S., Cowan, G., Meade, J. C., Wells, R. A., Stringer, J. R., Robson, K. J. (1993). A family of cation ATPase-like molecules from Plasmodium falciparum. J Cell Biol 120:385-398.
117. Krishna, S., Uhlemann, A. C., Haynes, R. K. (2004). Artemisinins: mechanism of action and potential for resistance. Drug Resist Updat 7:233-244.
118. Krishna, S., Woodrow, C. J., Staines, H. M., Haynes, R. K., Mercereau-Puijalon, O. (2006). Reevaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends Mol Med 12:200-205.
119. Krishna, S., Woodrow, C., Webb, R., Penny, J., Takeyasu, K., Kimura, M., et al. (2001). Expression and functional characterization of Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms. J Biol Chem 276:10782-10786.
120. Krungkral, S. R., Yuthavong, Y. (1987). Te antimalarial action on Plasmodium falciparum of qinghaosu andartesunate in combination with agents which modulate oxidant stress. Trans R Soc Trop Med Hyg 81:710-714.
121. Kurosawa, Y., Dorn, A., Kitsuji-Shirane, M., Shimada, H., Satoh, T., Matile, H., et al. (2000). Hematin polymerization assay as a high-throughput screen for identifcation of new antimalarial phar-macopheres. Antimicrob Agents Chemother 44:2638-2644.
122. L'Eplattenier, F. L., Murase, I., Martell, A. E. (1967). New multidentate ligands VI. Chelating tendencies of N,N'-di(2-hydroxybenzyl) ethylenediamine-N,N'-diacetic acid. J Am Chem Soc 89:837.
123. Ladan, H., Nitzan, Y., Malik, Z. (1993). Te antibacterial activity of haemin compared with cobalt, zinc, and magnesium protopor-phyrin and its efect on potassium loss and ultrastructure of Staphyloccocus aureus. FEMS Microbiol Lett 112:173-177.
124. Laing, A. B. (1970). Malaria suppression with fortnightly doses of pyrimethamine with sulfadoxine in the Gambia. Bull. World Health Organ 43:513-520.
125. Lambrose, C., Childs, G. E., Notsch, J. D., Scovill, J. P., Klayman, D. L, Davidson, D. E. Jr,. (1982). In vitro assessment of 2-acetylpyridine thiosemicarbazones against chloroquine-resistant Plasmodium falciparum. Antimicrob Agents Chemother 22:981-984.
126. Lankford, C. E. (1973). Bacterial assimilation of iron. CRC Crit Rev Microbiol 2:273.
127. Lau, E. H., Cerny, E. A., Wright, B. J., Rahman, Y. E. (1983). Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-di(2-hydroxybenzyl) ethylenediamine-N,N'-diacetic acid (HBED). Comparison with deferrioxamine. J Lab Clin Med 101:806-816. Laufer, R. B. (Ed.). (1992). Iron and human disease. Boca Raton, Florida, USA: CRC Press.
128. Laurent, S. A., Loup, C., Mourgues, S., Robert, A., Meunier, B. (2005). Heme alkylation by artesunic acid and trioxaquine DU1301, two antimalarial trioxanes. ChemBioChem 6:653-658.
129. Laurent, S. A., Robert, A., Meunier, B. (2004). C10-modifed artemisi-nin derivatives: efcient heme-alkylating agents. Angew Chem Int Ed Engl 44:2060-2063.
130. Levander, O. A., Ager, A. L., Jr., Morris, V. C., May, R. G. (1989). Qinghaosu, dietary vitamin E, selenium, and cod-liver oil: efect on the susceptibility of mice to the malarial parasite, Plasmodium yoelii. Am J Clin Nutr 50:346-352.
131. Loeb, R. F., Clark, W. M., Coatney, G. R., Coggenshall, L. T., Dieuaide, F. R., Dochez, A. R., et al. (1946). Activity of a new antimalarial agent, chloroquine (SN-7618). Statement approved by the Board for Coordination of Malarial Studies. J Am Med Assoc 30:1069.
132. Looareesuwan, S., Wilairatana, P., Vannaphan, S., Gordeuk, V. R., Taylor, T. E., Meshnick, S. R., et al. (1996). Coadministration of desferrioxamine B with artesunate in malaria: an assessment of safety and tolerance. Ann Trop Med Parasitol 90:551-554.
133. Loup, C., Lelièvre, J., Benoit-Vical, F., Meunier, B. (2007). Trioxaquines and heme-artemisinin adducts inhibit the in vitro formation of hemozoin better than chloroquine. Antimicrob Agents Chemother 51:3768-3770.
134. Lovejoy, D. B., Richardson, D. R. (2003). Iron chelators as antine-oplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem 10:1035-1049.
135. Loyevsky, M., Lytton, S. D., Mester, B., Libman, J., Shanzer, A., Cabantchik, Z. I. (1993). Te antimalarial action of desferal involves a direct access route to erythrocytic (Plasmodium falci-parum) parasites. J Clin Invest 91:218-224.
136. Lytton, S. D., Mester, B., Dayan, I., Glickstein, H., Libman, J., Shanzer A., et al. (1993). Mode of action of iron(III) chelators as antimalarials: 1. Membrane permeation properties and cyto-toxic activity. Blood 81:214-221.
137. Lytton, S. D., Mester, B., Libman, J., Shanzer, A., Cabantchik, Z. I. (1994). Mode of action of iron(III) chelators as antimalarials: II. Evidence for diferential efects on parasite iron-dependent nucleic acid synthesis. Blood 84:910-915.
138. McCormick, G. J. (1970). Amino acid transport and incorporation in red blood cells of normal and Plasmodium knowlesi-infected Rhesus monkeys. Exp Parasitol 27:143-149.
139. Meijler, M. M., Arad-Yellin, R., Cabantchik, Z. I., Shanzer, A. (2002). Synthesis and evaluation of iron chelators with masked hydrophilic moieties. J Am Chem Soc 124:12666-12667.
140. Meshnick, S. R. (1998). Artemisinin antimalarials: mechanism of action and resistance. Med Trop (Mars) 58:13-17.
141. Meshnick, S. R. (2002). Artemisinin: mechanisms of action, resistance, and toxicity. Int J Parasitol 32:1655-1660.
142. Meshnick, S. R., Taylor, T. E., Kamchonwongpaisan, S., (1996). Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 60:301-315.
143. Meshnick, S. R., Tomas, A., Ranz, A., Xu, C. M., Pan, H. Z. (1991). Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action. Mol Biochem Parasitol 49:181-190.
144. Meshnick, S. R., Tsang, T. W., Lin, F-B., Pan, H-Z., Chang, C-N., Kuypers, F., et al. (1989). Activated oxygen mediates the antima-larial activity of qinghaosu. Prog Clin Biol Res 313:95-104.
145. Meshnick, S. R., Yang, Y-Z., Lima, V., Kuypers, F., Kamchonwongpaisan, S., Yuthavong, Y. (1993). Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob Agents Chemother 37:1108-1114.
146. Mohanty, D., Ghosh, K., Pathare, A. V., Karnad, D. (2002). Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria. Ind J Med Res 115:17-21.
147. Montgomery, R., Eyles, D. E. (1963). Chloroquine resistant falciparum malaria in Malaya. Trans R Soc Trop Med Hyg 57:409-416.
148. Moore, D. V., Lanier, J. E. (1961). Observations on two Plasmodium falciparum infections with an abnormal response to chloro-quine. Am J Trop Med Hyg 10:5-9.
149. Murray, M. J., Murray, A. B., Murray, M. B., Murray, C. J. (1978). Te adverse efect of iron repletion on the course of certain infections. Br Med J 2:1113-1115.
150. Naegeli, H-U., Zähner, H. (1980). Metabolites of microorganisms. Part 193. Ferrithiocin. Helv Chim Acta 63:1400-1406.
151. Neilands, J. B. (1952). A crystalline organo-iron pigment from a rust fungus, Ustilago sphaerogena. J Am Chem Soc 74:4846.
152. Neufeld, E. J. (2006). Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 107:3436-3441.
153. Nick, H. P., Acklin, P., Faller, B., et al. (2000). ICL670A: a new, potent, orally active iron chelator. In: Bergeron, R., Badman, D., Brittenham, G. (Eds.), Iron chelators: new development strategies (pp 311-331). Ponte Vedra, Florida: Saratoga Publishers.
154. Nick, H. P., Acklin, P., Lattmann, R., Buehlmayer, P., Haufe, S., Schupp, J., et al. (2003). Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 10:1065-1076.
155. Nisbet-Brown, E., Olivieri, N. F., Giardina, P. F., et al. (2003). Efectiveness and safety of ICL670 in iron-loaded patients with thalassemia: a randomized, double-blind, placebo-controlled, dose-escalation trial. Lancet 361:1597-1602.
156. O'Neill, P. M., Posner, G H. (2004). A medicinal chemistry perspective on artemisinin and related endoperoxides. J Med Chem 47:2945-2964.
157. Oblander, M., Carpentieri, U. (1991). Growth, ribonucleotide reductase, and metals in murine leukemic lymphocytes. J Cancer Res Clin Oncol 117:444.
158. Okada, R. (2008). Te novel heme oxygenase-like protein from Plasmodium falciparum converts heme to bilirubin IXa in the apicoplast. FEBS Lett 583:313-319.
159. Olivieri, N. F., Brittenham, G. M., McLaren, C. E., Templeton, D. M., Cameron, T. G, McClelland, R. A., et al. (1998). Long-term safety and efectiveness of iron-chelation therapy with deferiprone for thalassemia major. NEJM 339:417-423.
160. Olivieri, N. F., Koren, G., St., Louis, P., Freedman, M. H., McClelland, R. A., Templeton, D. M. (1990). Studies of the oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in thalassemia patients. Semin Hematol 27:101-104. (Pubitemid 20141854)
161. Olliaro, P. L., Haynes, R. K., Meunier, B., Yuthavong, Y. (2001). Possible modes of action of the artemisinin-type compounds. Trends Parasitol 17:122-126.
162. Olliaro, P. L., Taylor, W. R. J. (2003). Review. Antimalarial compounds: from bench to bedside. J. Exp. Biol. 206:3753-3759.
163. Olliaro, P. L., Taylor, W. R. J. (2004). Developing artemisinin-based drug combinations for the treatment of drug-resistant falciparum malaria: a review. J Postgrad Med 50:40-44.
164. Oppenheimer, S. J., MacFarlane, S. B. J., Moody, J. B., Bunari, O., Hendrickse, R. G. (1986). Efect of iron prophylaxis on morbidity due to infectious disease. Report on clinical studies in Papua New Guinea. Trans Roy Soc Trop Med Hyg 80:596-602.
165. Orjih, A. U., Banyal, H. S., Chevli, R., Fitch, C. D. (1981). Hemin lyses malaria parasites. Science 214:667-669.
166. Pagola, S., Stephens, P. W., Bohle, D. S., Kosar, A. D., Madsen, S. K. (2000). Te structure of malaria pigment fj-haematin. Nature 404:307-310.
167. Pandy, A. V, Singh, N., Tekwani, B. L., Puri, S. K., Chauhan, V. S. (1999a). Assay of fj-hematin formation by malaria parasite. J Pharm Biomed Anal 20:203-207.
168. Pandy, A. V, Tekwani, B. L., Singh, R. L., Chauhan, V. S. (1999b). Artemisinin, and endoperoxides antimalarial, disrupts the hemoglobin catabolism and heme detoxifcation systems in malarial parasites. J Biol Chem 274:189383-219388
169. Parapini, S., Basilico, N., Mondani, M., Olliaro, P., Taramelli, D., Monti, D. (2004). Evidence that haeme iron in the malaria parasite is not need for the antimalarial efects of artemisinin. FEBS Lett 575:91-94.
170. Parkin, J. D., Rush, B., DeGroot, R. J., Budd, R. S. (1974). Iron absorption after splenectomy in hereditary spherocytosis. Austral New Zeal J Med 4:58-61.
171. Peto, T. E. A., Tompson, J. L. (1986). A reappraisal of the efects of iron and desferrioxamine on the growth of Plasmodium falciparum in vitro:the unimportance of serum iron. Br J Haematol 63:273.
172. Pisciotta, J. M., Sullivan, D. (2008). Hemozoin: oil versus water. Parasitol Int 57:89-96.
173. Pollack, S., Rossan, R. N., Davidson, D. E., Escajadillo, A. (1987). Desferrioxamine suppresses Plasmodium falciparum in Aotus monkeys. Proc Soc Exp Biol Med 184:162-164.
174. Pollack, S., Schnelle, V. (1988). Inability to detect transferrin receptors on P. falciparum parasitized red cells. Br J Haematol 68:125.
175. Ponka, P., Borová, J., Neuwirt, J., Fuchs, O., Necas, E. (1979b). A study of intracellular iron metabolism using pyridoxal isonico-tinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 586:278-297.
176. Ponka, P., Borová, J., Neuwirt, J., Fuchs, O. (1979a). Mobilization of iron from reticulocytes. Identifcation of pyridoxal isonicotinoyl hydrazone as a new iron-chelating agent. FEBS Lett 15:317-321.
177. Ponmee, N., Chuchue, T., Wilairat, P., Yuthavong, Y., Kamchonwongpaisan, S. (2007). Atermisinin efectiveness in erythrocyte is reduced by heme and heme-containing proteins. Biochem Pharmacol 74:153-160.
178. Pootrakul, P., Rugiatsakul, R., Wasi, P. (1980). Increased transferrin iron saturation in splenectomized thalassemic patients. Br J Haematol 46:143-145.
179. Posey, J. E., Gherardini, F. C. (2000). Lack of a role for iron in the Lyme disease pathogen. Science 288:1651-1653.
180. Posner, G. H., Oh, C. H., Gerena, L., Milhous, S. R. (1992). Extraordinarily potent antimalarial compounds: new, structurally simple, easily synghesized tricyclic 1,2,4-trioxanes. J Med Chem 35:2459-2467.
181. Posner, G. H., Oh, C. H., Wang, D., Gerena, L., Milhous, W. K., Meshnick, S. R., et al. (1994). Mechanism-based design, synthesis, and in vitro antimalarial testing of new 4-methylated trioxanes structurally related to artemisinin: the importance of carbon-centered radical for antimalarial activity. J Med Chem 37:1256-1258.
182. Pouvelle, B., Spiegel, R., Hsiao, L., Howard, R. J., Morris, R. L., Tomas, A. P., et al. (1991). Direct access to serum macromol-ecules by intraerythrocytic malaria parasites. Nature (Lond) 353:73-75.
183. Pradines, B., Ramiandrasoa, F., Basco, L. K., Bricard, L., Kunesch, G., Le Bras J., (1996). In vitro activities of novel catecholate siderophores against Plasmodium falciparum. Antimicrob Agents Chemother 40:2094-2098.
184. Pradines, B., Ramiandrasoa, F., Rolain, J. M., Rogier, C., Mosnier, J., Daries, W., et al. (2002a). In vitro potentiation of antibiotic activities by a catecholate iron chelator against chloroquine-re-sistant Plasmodium falciparum. Antimicrob Agents Chemother 46:225-228.
185. Pradines, B., Rolain, J. M., Famiandrasoa, F., Fusai, T., Mosnier, J., Rogier, C., et al. (2002b). Iron chelators as antimalarial agents: in vitro activity of dicatecholate against Plasmodium falciparum. J Antimicrob Chemother 50:177-187.
186. Pradines, B., Tall, A., Ramiandrasoa, F., Spiegel, A., Sokhna, C., Fusai, T., et al. (2005). In vitro activity of iron-binding compounds against Senegalese isolates of Plasmodium falciparum. J Antimicrob Chemother 57:1093-1099.
187. Pradines, B., Tall, A., Ramiandrasoa, F., Spiegel, A., Sokhna, C., Fusai, T., et al. (2006). In vitro activity of iron-binding compounds against sengalese isolates of Plasmodium falciparum. J Antimicrob Chemother 57:1093-1099.
188. Prescott, B. (1975). Tiosemicarbasones and hydrazones of alpha-methylchalkone as potential chemotherapeutic agents. Int J Clin Pharmacol Biopharm 11:332-335.
189. Prescott, B., Lones, G., Peacock, C. L., Caldes, G. (1969). 4-(1-adamantyl)-3-thiosemicarbazones as potential chemothera-peutic agents. Antimicrob Agents Chemother 9:275-279.
190. Piscotta, J. M., Sullivan, D. (2008). Hemozoin: oil versus water. Parasitol Int 57:89-96.
191. Qinghoasu Antimalaria Coordinating Research Group. (1979). Antimalaria studies of qinghaosu. Chin Med J (Engl) 92:811-816.
192. Rahman, Y. E., Cerny, E. A., Lau, E. H., Carnes, B. A. (1983). Enhanced iron removal from liver parenchymal cells in experimental iron overload: liposome encapsulation of HBED and phenobarbital administration. Blood. 1:209-213.
193. Raventos-Suarez, C., Pollack, S., Nagel, R. L. (1982). Plasmodium falciparum:inhibition of in vitro growth by desferrioxamine. Am J Trop Med Hyg 5:919-922.
194. Robert, A., Benoit-Vical, F., Claparols, C., Meunier, B. (2005). Te antimalarial drug, artemisinin, alkylates heme in infected mice. Proc Natl Acad Sci U S A 102:13676-13680.
195. Robert, A., Cazelles, J., Meunier, B. (2001). Characterization of the alkylation product of heme by the antimalarial drug artemisi-nin. Angewandte Chem Int Ed 40:1954-1957.
196. Robert, A., Coppel, Y., Meunier, B. (2002). Alkylation of heme by the antimalarial drug artemisinin. Chem Commun (Camb) 5:414-415. (Pubitemid 34252451)
197. Rodriguez, M., Claparols, C., Robert, A., Meunier, B. (2002). Alkylation of microperoxidase-11 by the antimalarial drug artemisinin. ChemBioChem 3:1147-1149. (Pubitemid 36008049)
198. Rubin, H., Salem, S. S., Lin-Sheng, L., Yang, F., Mama, S., Wang, Z., et al. (1993). Cloning, sequence determination, and regulation of the ribonucleotide reductase subunits from Plasmodium falciparum:a target for antimalarial therapy. Proc Natl Acad Sci U S A 90:9280.
199. Sandosham, A. A. (1963). Chloroquine-resistant falciparum malaria in Malaya. Singapore Med J 4:3-5.
200. Santos, A. S., Pisciotta, A. V. (1964). Acute iron intoxication. Treatment with desferrioxamine (Ba-29837). Am J Dis Child 107:424-427.
201. Savulescu, J. (2004). Talassemia major: the murky story of deferiprone. Br Med J 328:358-359.
202. Sazawal, S., Black, R.E., Ramsam, M., Chwaya, H. M., Stoltsfus, R. J., Dutta, A., et al. (2006). Efects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malarial transmission setting: community-based, randomized, placebo-controlled trial. Lancet 367:133-143. (Pubitemid 43077129)
203. Scheibel, L. W., Adler, A. (1980). Antimalarial activity of selected aromatic chelators. Mol Pharmacol 18:320-325.
204. Schmidt, L. H. (1953). [Cited in Wilson, T., Edeson, J. F. B. (1953).] Treatment of acute malaria with pyrimethamine. Br Med J 31:253-255.
205. Schnebli, H. P. (1998). CGP 72 670, a new, potent, orally active iron chelator [abstract]. ISH-EHA Combined Haematology Congress, Amsterdam, Te Netherlands. Br J Haematol 102:1121a.
206. Schumann, R. R. (2007). Malarial fever: hemozoin is involved but Toll-free. Proc Natl Acad Sci U S A 104:1743-1744.
207. Scott, M.D., Ranz, A., Kuypers, F. A., Lubin, B. H., Meshnick, S. R. (1990). Parasite uptake of desferroxamine: a prerequisite for antimalarial activity. Br J Haematol 75:598-602.
208. Scovill, J. P., Klayman, D. L., Franchino, C. F. (1982). 2-acetylpyridine thiosemicarbazones. 4. Complexes with transition metals as anti-malarial and antileukemic agents. J Med Chem 25:1261-1264.
209. Scovill, J. P., Klayman, D. L., Lambros, C., Childs, G. E., Notsch, J. D. (1984). 2-acetylpyridine thiosemicarbazones. 9. Derivatives of 2-acetylpyridine 1-oxide as potential antimalarial agents. J Med Chem 27:87-91.
210. Selmeczi, K., Robert, A., Claparois, C., Meunier, B. (2004). Alkylation of human hemoglobin A0 by the antimalarial drug artemisinin. FEBS Lett 556:245-248.
211. Sergejew, T., Forgiarini, P., Schnebli, H. P. (2000). Chelator-induced iron excretion in iron-overloaded marmosets. Br J Haematol 111:985-992.
212. Shanzer, A., Libman, J., Lytton, S. D., Glickstein, H., Cabantchik, Z. I. (1991). Reversed siderophores act as antimalarial agents. Proc Natl Acad Sci U S A 88:6585-6589.
213. Sherman, I. W., Tanigoshi, L. (1970). Incorporation of 14C amino acids by malaria (Plasmodium iophurae). Int J Biochem 1:635-637.
214. Sherman, I. W., Zidovetzky, R. (1992). A parasitophorus duct in Plasmodium-infected red blood cells. Parasitol Today 8:2-3.
215. Singh, C., Arif, A. J., Mathur, P. D., Chandra, S., Sen, A. B. (1985). Efect of a specifc iron chelator, desferrioxamine, on the host biochemistry and parasitemia in mice infected with Plasmodium berghei. Ind J Malariol 22:35-44.
216. Singh, J., Ray, A. P., Basu, P. C., Misra, B. G. (1952). Efect of pyrimeth-amine in human malaria. 1. Ind J Malariol 6:435-440.
217. Slater, A. F. G., Swiggard, W. J., Orton, B. R., Filter, W. D., Goldberg, D., Cerami, A., et al. (1991). An iron-carboxylate bond links the heme units of malaria pigment. Proc Natl Acad Sci U S A 88:325.
218. Smith, A. M., Hendrickse, R. G., Harrison, C., Hayes, R. J., Greenwood, B. M. (1989). Te efects on malaria of treatment of iron defciency anaemia with oral iron in Gambian children. Ann Trop Paediatr 9:17-23.
219. Solomon, V. R., Haq, W., Puri, S. K., Srivastava, K., Katti, S. B. (2006). Design, synthesis and antimalarial activity of a new class of iron chelators. Med Chem 2:133-138.
220. Srivastava, P., Pandey, V. C. (1995). Haem oxygenase and related indicies in chloroquine-resistant and sensitive strains of Plasmodium berghei. Int J Parasitol 25:1061-1064.
221. Stahel, E., Mazier, D., Guillouzo, A., Miltgen, F., Landau, I., Mellouk, S., et al. (1988). Iron chelators: in vitro inhibitory efect on the liver stage of rodent and human malaria. Am J Trop Med Hyg 39:236-240.
222. Taraschi, T. F., Pouvelle, B., Howard, R. J. (1992). A parasitophorus duct in Plasmodium-infected red blood cells: a reply. Parasitol Today 8:17.
223. Tekwani, B. L., Walker, L. A. (2005). Targeting the hemozoin synthesis pathway for new antimalarial drug discovery: technologies for in vitro beta-hematin formation assay. Comb Chem High Troughput Screen 8:63-79.
224. Tuma, PE, Olivieri, NF, Mabeza, G F, Biemba, G, Parry, D, Zulu, S, et al. (1998b). Assessment of the efect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum para-sitemia in humans. Am J Trop Med Hyg 58:358-364.
225. Tuma, P. E., Mabeza, G. F., Biemba, G., Bhat, G. J., McLaren, C. E., Moyo, V. M., et al. (1998a). Efect of iron chelation therapy on mortality in Zambian children with cerebral malaria. Trans R Soc Trop Med Hyg 92:214-218.
226. Traore, O., Carnevale, P., Kaptue-Noche, L., M'Bede, J., Desfontaine, M., Elion, J., et al. (1991). Preliminary report on the use of desferrioxamine in the treatment of Plasmodium falci-parum malaria. Am J Haematol 37:206-208.
227. Trottein, F., Tompson, J., Cowman, A. F. (1995). Cloning of a new cation ATPase from Plasmodium falciparum:conservation of critical amino acids involved in calcium binding in mammalian organellar Ca2+-ATPases. Gene 158:133-137.
228. Tsafack, A., Golenser, J., Libman, J., Shanzer, A., Cabantchik, Z. I. (1995). Mode of action of iron(III) chelators as antimalarials. III. Overadditive efects in the combined action of hydroxamate-based agents on in vitro growth of Plasmodium falciparum. Mol Pharmacol 47:403-409.
229. Uhlemann, A-C., Cameron, A., Eckstein-Ludwig, U., Fischbarg, J., Iserovich, P., Zuinga, F. A., et al. (2005). A single amino acid residue can determine the sensitivity of SERCAs to artemisinin. Nat Struct Mol Biol 12:628-629.
230. Uhlemann, A-C., Wittlin, S., Matile, H., Bustamante, L. Y., Krishna, S. (2007). Mechanism of antimalarial action of the synthetic tri-oxolane RBX11160 (OZ277). Antimicrob Agents Chemother 51:667-672.
231. Urban, B. C., Todryk, S. (2006). Malaria pigment paralyzes dendritic cells. J Biol 5:4.
232. Walcourt, A., Loyevsky, M., Lovejoy, D. B., Gordeuk, V. R., Richardson, D. R. (2004). Novel aroylhydrazone and thiosemi-carbazone iron chelators with anti-malarial activity against chloroquine-resistant and-sensitive parasites. Int J Biochem Cell Biol 36:401-407.
233. Warhurst, D. C. (1987). Antimalarial drugs. An update. Drugs. 33:50-65.
234. Weinberg, E. D. (1974). Iron and susceptibility to infectious disease. Science 184:952-956.
235. Weinberg, E. D. (1984). Iron withholding: a defense against infection and neoplasia. Physiol Rev 64:65-102.
236. Weinberg, E. D. (1998). Patho-ecological implications of microbial acquisition of host iron. Rev. Med. Microbiol. 9:171-178.
237. Weinberg, E. D. (2005). Iron withholding as a defense strategy. In: Weiss, G., Gordeuk, V. R., Hershko, C. (Eds.), Anemia of chronic disease (pp 255-280). Boca Raton, Florida, USA: Taylor & Francis.
238. Wilson, T., Edeson, J. F. B. (1953). Treatment of acute malaria with pyrimethamine. Br Med J 31:253-255. Wiselogle, F. Y. (Ed.). (1946). A survey of antimalarial drugs, 1942-1945. Ann Arbor, Michigan, USA: J.W. Edwards.
239. Whitehead, S., Peto, T. E. A. (1990). Stage-dependent efect of deferoxam-ine on growth of Plasmodium falciparum in vitro. Blood 76:1250.
240. Whitten, C. F., Gibson, G. W., Good, M. H., Goodwin, J. F., Brough, A. J. (1965). Studies in acute iron poisoning. I. Desferrioxamine in the treatment of acute iron poisoning: clinical observations, experimental studies, and theoretical considerations. Pediatrics 36:322-335.
241. Wolfensberger, H. R. (1971). Curative and suppressive treatment of P. falciparum malaria with oral and parenteral Fansidar. Southeast Asian J Trop Med Pub Health 2:39-43.
242. Wolfensberger, H. R. (1972). Suppressive and curative trials in Plasmodium malaria infection with Fansidar. East Afr Med J 49:338-345.
243. Woodrow, C. J., Haynes, R. K., Krishna, S. (2004). Artemisinins. Postgrad Med J 81:71-78.
244. Woodrow, C. J., Krishna, S. (2006). Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical signifcance. Cell Mol Life Sci 63:1586-1596.
245. Wu, Y. (2002). How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemist's view. Acc Chem Res 35:255-259.
246. Wu, Y., Yue, Z. Y., Wu, Y. L. (1999). Interaction of qinghaosu (artem-isinin) with cystein sulfhydryl mediated by traces of non-heme iron. Angew Chem Int Ed Engl 38:2580-2582.
247. Yiakouvaki, A., Savovic, J., Al-Qenaei, A., Dowden, J., Pourzand, C. (2006). Caged-iron chelators a novel approach towards protecting skin cells against UVA-induced necrotic cell death. J Invest Dermatol 126:2287-2295.
248. Yinnon, A. M., Teanacho, E. N., Grady, R. W., Spira, D. T., Hershko, C. (1989). Antimalarial efect of HBED and other phenolic and cat-echolic iron chelators. Blood 74:2166-2177.